Ligand Pharmaceuticals Projects Robust Royalty Revenue Growth by 2029

Published 1 hours agoLGND

Ligand Pharmaceuticals Projects Robust Royalty Revenue Growth by 2029

Ligand Pharmaceuticals has shared an ambitious financial outlook, revealing plans for a compound annual growth rate of at least 22% in royalty revenues through 2029. The company aims to achieve approximately $285 million in royalty receipts by that year, according to Nasdaq.com. This projection is part of a broader strategy that includes leveraging its research and development investments and technology platforms such as Captisol® and NITRICIL™.

In its 2025 financial guidance, Ligand expects total revenues to range between $180 million and $200 million, with royalty revenues contributing $135 million to $140 million. The company is also forecasting $35 million to $40 million in Captisol sales and $10 million to $20 million in contract revenue. For adjusted earnings per share, Ligand has set a target of $6.00 to $6.25. Nasdaq.com notes that key commercial programs like Filspari and Veklury are among those projected to drive this growth.

Recent strategic initiatives include significant investments totaling $192 million in the past two years across eight ventures, alongside evaluating over $1 billion in potential opportunities. Ligand Pharmaceuticals is focused on expanding its royalty portfolio and exploiting its technological platforms to secure substantial revenue growth in the coming years. By capitalizing on existing and emerging collaborations, the company aims to enhance its market position significantly.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Scotiabank Lowers Price Target for Geron Amid Rytelo Sales Concerns

Scotiabank Lowers Price Target for Geron Amid Rytelo Sales Concerns

28 minutes agoGERN

Scotiabank recently downgraded its price target for Geron Corporation, reflecting concerns over the sales performance of the company's blood cancer drug, Rytelo. The price target was reduced from $6.00 to $4.00, while maintaining a 'Sector Outperform' rating. This adjustment comes in the wake of Geron's fourth-quarter 2024 results, which met expectations but showed a slower-than-hoped launch momentum for Rytelo in treating lower-risk myelodysplastic syndromes (LR-MDS). This development underscores the challenges Geron faces in the competitive oncology market. The company's current stock price stands at $1.275, representing a slight decrease from its previous close. As reported by Scotiabank, the market remains vigilant following the drug's performance indicators, which play a crucial role in influencing investor sentiment. Despite the lowered price target, Scotiabank's retention of a 'Sector Outperform' rating signals sustained confidence in Geron's long-term potential. The bank's outlook suggests that while immediate sales trajectories pose worries, the broader investment case for Geron remains positive. This indicates that investors might still find value in Geron's strategic initiatives and future growth prospects.

Teradyne Declares $0.12 Dividends and Expands Share Buyback Program

Teradyne Declares $0.12 Dividends and Expands Share Buyback Program

43 minutes agoTER

Teradyne, Inc. has announced a quarterly cash dividend of $0.12 per share, continuing its regular return of capital to investors. This dividend is slated to be paid on March 14, 2025, with shareholders needing to be on record by February 14, 2025, and the ex-dividend date set for February 13, 2025. The company's annualized dividend yield stands at approximately 0.4%. In a related financial move, Teradyne is expanding its share repurchase efforts, adding up to $100 million to its existing buyback program for the remainder of 2024. This extension is part of a broader $2 billion initiative, extending beyond merely offsetting potential stock dilution from equity compensation and employee share purchases. These financial commitments highlight Teradyne's robust fiscal strategy and its dedication to delivering value to shareholders. According to Business Wire, the expansion of the share buyback program reflects the company's belief in its long-term prospects and its strategy to maximize shareholder returns.

Shopify's Stock Dips Amidst Mixed Financial Outlook

Shopify's Stock Dips Amidst Mixed Financial Outlook

58 minutes agoSHOP

Shopify's stock is under pressure in premarket trading, dropping over 6%, as the company issued its latest financial forecasts. This movement comes as Shopify projects its second-quarter revenue to grow in the mid-20% range, slightly exceeding the analysts' average expectation of 22.4%, according to Reuters. However, it's not all positive news. Shopify's projection for gross profit growth is set to rise at a high-teen percentage rate, falling short of analysts' expectations of a 20.2% increase. These mixed signals have contributed to volatility in the company's stock performance, which currently sits at $91.29 per share, showing a decrease of $3.96 from its previous close. The intraday performance has witnessed a high of $99.24 and a low of $84.9, with a significant trading volume of 19,518,304 shares. Shopify's strategic outlook remains focused on solidifying its revenue streams while managing profit margins within a competitive market. The latest trading figures underscore the market's cautious response to the company's financial guidance, emphasizing the balance Shopify seeks to maintain between growth expectations and profitability targets.

Insmed Sees Growth in ARIKAYCE Sales and Advances Brensocatib Development

Insmed Sees Growth in ARIKAYCE Sales and Advances Brensocatib Development

1 hours agoINSM

Insmed Incorporated has reported significant growth in its financial performance, particularly in the global net product sales of ARIKAYCE. In 2024, sales reached approximately $363.7 million, a notable 19% increase from the previous year. The company anticipates this growth trend to continue, projecting global ARIKAYCE revenues to range between $405 million and $425 million in 2025, according to stocktitan.net. Alongside financial gains, Insmed is making strides in drug development. The FDA has accepted the New Drug Application for brensocatib, designed for patients with bronchiectasis, and has granted it priority review with an expected action date of August 12, 2025. Reuters reported that, subject to approval, Insmed plans to launch brensocatib in the U.S. by mid-2025, with releases in Europe and Japan set for the first half of 2026. Insmed's strategic focus includes hefty investment into product commercialization and widening its global reach. As of the end of 2024, the company held cash and securities amounting to $1.4 billion. This solid financial footing supports their ongoing plans for the U.S. launch of brensocatib and further development of clinical trial programs in 2025 as noted on Nasdaq.com. These efforts highlight Insmed's commitment to both product expansion and financial growth.